RightFit
RecruitingPhase 2

Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders

Clinical Trial on the Use of Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years to 50 Years
Sex
Female only
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study tests ravulizumab to treat severe preeclampsia, a serious high blood pressure problem during pregnancy, and HELLP syndrome, which affects blood cells and the liver. It is for people who are less than 34 weeks pregnant and have signs of either condition.

The researchers are testing a medication named ravulizumab for the treatment of severe preeclampsia and Hemolysis, Elevated Liver enzymes, Low Platelets (HELLP) syndrome.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Less than 34 weeks pregnant.
  • Have signs of severe preeclampsia or HELLP syndrome.

Who can't join

  • Have DIC, a serious problem with blood clotting.
  • The baby's condition requires delivery, the baby cannot survive, or the baby has died in the womb.
  • Less than 23 weeks pregnant.
  • Have had a stroke.
  • Have known atypical hemolytic uremic syndrome, a disease that damages blood cells and kidneys.
  • Have inherited or acquired thrombocytopenia purpura, a disorder with low levels of blood-clotting cells.
  • Have paroxysmal nocturnal hemoglobinuria, a disease that destroys red blood cells.
  • Are allergic to ravulizumab, or cannot or do not want to sign the form agreeing to join the study.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: * Individuals with \< 34 0/7 weeks of gestation. * Individuals with severe preeclampsia or HELLP features. Exclusion Criteria: * Pregnant female patients presenting with disseminated intravascular coagulopathy (DIC). * Individuals with non-reassuring fetal status requiring delivery, non-viable fetuses, previable pregnancy (\<23 0/7 weeks gestation), stroke, in utero fetal demise, known atypical hemolytic uremic syndrome, familial or acquired thrombocytopenia purpura, paroxysmal nocturnal hemoglobinuria, allergy to Ravulizumab, inability or unwillingness to sign informed consent.

Study sites (1)

MN